Dabigatran - CAS 211914-51-1
Catalog number:
B0084-102023
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C25H25N7O3
Molecular Weight:
471.51
COA:
Inquire
Targets:
Thrombin
Description:
Dabigatran is a very potent anticoagulant, shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of activity.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-102023 250 mg $168 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
BIBR 953
MSDS:
Inquire
1.Management of bleeding complications in patients with cancer on DOACs.
Schulman S1, Shrum J2, Majeed A3. Thromb Res. 2016 Apr;140 Suppl 1:S142-7. doi: 10.1016/S0049-3848(16)30113-X.
There has been a concern that major bleeding events (MBE) on direct-acting oral anticoagulants (DOACs) will be more difficult to manage than on vitamin K antagonists. Patients with cancer and DOAC-associated bleeding may be even more of a challenge to manage. We therefore reviewed the literature on bleeding in patients with cancer on DOACs. In addition, we performed an analysis of individual patient data from 5 phase III trials on treatment with dabigatran with focus on those with cancer. In 6 randomized trials the risk of MBE in patients with cancer was similar on treatment with DOACs compared to vitamin K antagonists. Bleeding was in the majority of patients managed with supportive therapy alone. In the individual patient data analysis there were no significant differences in use of hemostatic products, transfusion of red cells, effectiveness of management, bleeding-related mortality or 30-day all-cause mortality between patients with cancer treated with dabigatran or with warfarin.
2.Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Harenberg J1. Thromb Res. 2016 Apr;140 Suppl 1:S165-7. doi: 10.1016/S0049-3848(16)30117-7.
A two-fold prolongation of activated partial thromboplastin time (APTT) is established as therapeutic range for therapy with unfractionated heparin, hirudin and argatroban. The international normalized ratio (INR) of 2 to 3 is required to maintain anticoagulation in the therapeutic range of vitamin K antagonists. The therapeutic range of anti-factor Xa activity during therapy with low-molecular weight heparins and danaparoid are less well and of direct oral anticoagulants (DOAC) poorly defined. The relation of aPTT and INR values to thrombotic and bleeding events are well established despite a large variation of values in affected patients. The relation of coagulation values of the other anticoagulants to clinical events is open. The value of determination in cancer patients is higher because of the increased risk for thrombotic and bleeding events of this patient group. Several activities are currently undertaken to certify methods for in vitro diagnostic testing for DAOCs.
3.Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Spronk HM1, De Jong AM2, Verheule S3, De Boer HC4, Maass AH2, Lau DH3, Rienstra M2, van Hunnik A3, Kuiper M3, Lumeij S3, Zeemering S3, Linz D5, Kamphuisen PW6, Ten Cate H1, Crijns HJ7, Van Gelder IC2, van Zonneveld AJ4, Schotten U8. Eur Heart J. 2016 Apr 12. pii: ehw119. [Epub ahead of print]
AIMS: Atrial fibrillation (AF) produces a hypercoagulable state. Stimulation of protease-activated receptors by coagulation factors provokes pro-fibrotic, pro-hypertrophic, and pro-inflammatory responses in a variety of tissues. We studied the effects of thrombin on atrial fibroblasts and tested the hypothesis that hypercoagulability contributes to the development of a substrate for AF.
4.Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R1, Kavtaradze A1, Gupta A2, Ghosh RK3. Int J Cardiol. 2016 Mar 28;214:292-298. doi: 10.1016/j.ijcard.2016.03.056. [Epub ahead of print]
The Vitamin K antagonist warfarin was the only oral anticoagulant available for decades for the treatment of thrombosis and prevention of thromboembolism until Direct Oral Anticoagulants (DOACs); a group of new oral anticoagulants got approved in the last few years. Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade. DOACs have many advantages over warfarin. However, the biggest drawback of DOACs has been the lack of specific antidotes to reverse the anticoagulant effect in emergency situations. Activated charcoal, hemodialysis, and activated Prothrombin Complex Concentrate (PCC) were amongst the nonspecific agents used in a DOAC associated bleeding but with limited success. Idarucizumab, the first novel antidote against direct thrombin inhibitor dabigatran was approved by US FDA in October 2015. It comprehensively reversed dabigatran-induced anticoagulation in a phase I study.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Thrombin Products


VE-1902

VE-1902 is a novel and selective inhibitor of thrombin. Study in vivo and in vitro showed that VE-1902 inhibits thrombin via binding to it reversibly.

CAS 83997-16-4 GYKI 14166

GYKI 14166
(CAS: 83997-16-4)

Efegatran is a thrombin inhibitor under the development of Eli Lilly. It can be used for the treatment of thromboembolic disorders. No development reported was ...

CAS 137215-12-4 odiparcil

odiparcil
(CAS: 137215-12-4)

Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant. Research for th...

H-D-Phe-Pro-arginal
(CAS: 60503-05-1)

H-D-Phe-Pro-arginal is a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders. It has a similar efficacy ...

CAS 74863-84-6 Argatroban

Argatroban
(CAS: 74863-84-6)

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.

CAS 872728-81-9 Dabigatran etexilate mesylate

Dabigatran etexilate mesylate
(CAS: 872728-81-9)

Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. It is a reversible and selective, direct thrombin inhibitor (DTI).

CAS 871576-03-3 Flovagatran

Flovagatran
(CAS: 871576-03-3)

Flovagatran is a thrombin inhibitor originated by Trigen Holdings AG. In Dec 2010, Phase-II for Thrombosis was discontinued.

CAS 137339-65-2 Sfllrnpndkyepf

Sfllrnpndkyepf
(CAS: 137339-65-2)

SFLLRNPNDKYEPF is a synthetic thrombin receptor agonist peptide and causes platelet aggregation (EC50 = 4 μM) and secretion .

GYKI14451
(CAS: 69201-89-4)

GYKI14451 is a synthetic tripeptide inhibitor of thrombin. It has anti-atherosclerotic activity.

CAS 496775-62-3 Eltrombopag Olamine

Eltrombopag Olamine
(CAS: 496775-62-3)

Eltrombopag is a is an agonist of the c-mpl (TpoR) receptor used as treatment for thrombocytopenia.It has been developed for certain conditions that lead to thr...

CAS 141396-28-3 Argatroban

Argatroban
(CAS: 141396-28-3)

Argatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with ...

CAS 211914-51-1 Dabigatran

Dabigatran
(CAS: 211914-51-1)

Dabigatran is a very potent anticoagulant, shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of...

CAS 211915-06-9 Dabigatran Etexilate

Dabigatran Etexilate
(CAS: 211915-06-9)

Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki va...

CAS 429658-95-7 Dabigatran ethyl ester

Dabigatran ethyl ester
(CAS: 429658-95-7)

Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. Dabigatran provides a stable anticoagulation effect w...

CAS 192939-46-1 Ximelagatran

Ximelagatran
(CAS: 192939-46-1)

Ximelagatran, an ester prodrug of melagatran, with anticoagulant effect, is the first member of direct thrombin inhibitors that can be taken orally.

GYKI-14451 sulfate
(CAS: 83861-29-4)

GYKI-14451 is a synthetic tripeptide inhibitor of thrombin.It has anti-atherosclerotic activity.

Bivalirudin Trifluoroacetate

Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding ...

CAS 30827-99-7 AEBSF HCl

AEBSF HCl
(CAS: 30827-99-7)

AEBSF is a water soluble, irreversible serine protease inhibitor; inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.

Chemical Structure

CAS 211914-51-1 Dabigatran

Quick Inquiry

Verification code

Featured Items